EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies

Eiji Kobayashi, Yusuke Kamihara iD, Miho Arai, Akinori Wada iD, Shohei Kikuchi iD, Ryo Hatano iD, Noriaki Iwao, Takeshi Susukida iD, Tatsuhiko Ozawa, Yuichi Adachi, Hiroyuki Kishi iD, Nam H Dang und 4 weitere

Cells · 14.08.2023 · 12 (16) · 2059

DOI: 10.3390/cells12162059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 14.08.2023. Verfasst von Eiji Kobayashi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, T-Cell. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency (JST), Japan Agency for Medical Research and Development (AMED), Japan Society for the Promotion of Science (JSPS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is already widely adopted in clinical practice. On the other hand, the development of CAR-T-cell therapy for T-cell malignancies is in its nascent stage. One of the potential targets is CD26, to which we have developed and evaluated the efficacy and safety of the humanized monoclonal antibody YS110. We generated second (CD28) and third (CD28/4-1BB) generation CD26-targeted CAR-T-cells (CD26-2G/3G) using YS110 as the single-chain variable fragment. When co-cultured with CD26-overexpressing target cells, CD26-2G/3G strongly expressed the activation marker CD69 and secreted IFNgamma. In vitro studies targeting the T-cell leukemia cell line HSB2 showed that CD26-2G/3G exhibited significant anti-leukemia effects with the secretion of granzymeB, TNFα, and IL-8, with 3G being superior to 2G. CD26-2G/3G was also highly effective against T-cell lymphoma cells derived from patients. In an in vivo mouse model in which a T-cell lymphoma cell line, KARPAS299, was transplanted subcutaneously, CD26-3G inhibited tumor growth, whereas 2G had no effect. Furthermore, in a systemic dissemination model in which HSB2 was administered intravenously, CD26-3G inhibited tumor growth more potently than 2G, resulting in greater survival benefit. The third-generation CD26-targeted CAR-T-cell therapy may be a promising treatment modality for T-cell malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenLymphoma, T-CellAnimalsMiceT-LymphocytesCD28 AntigensDipeptidyl Peptidase 4Antibodies, MonoclonalCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

CAR-TCD26T-cell malignanciesfratricidethird-generation

Substanzen

Receptors, Chimeric AntigenCD28 AntigensDipeptidyl Peptidase 4Antibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
  • Department of Hematology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
  • Department of Pediatrics, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
  • Department of Hematology, Juntendo University Shizuoka Hospital, Izunokuni City, Shizuoka 410-2211, Japan.
  • Division of Host Defences, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.

ORCID-Profile: Yusuke Kamihara, Akinori Wada, Shohei Kikuchi, Ryo Hatano, Takeshi Susukida, Hiroyuki Kishi, Yoshihiro Hayakawa

Förderung

  • Japan Science and Technology Agency (JST)
  • Japan Agency for Medical Research and Development (AMED)
  • Japan Society for the Promotion of Science (JSPS)

Zitieren

APA

Kobayashi, E., Kamihara, Y., Arai, M., Wada, A., Kikuchi, S., Hatano, R., Iwao, N., Susukida, T., Ozawa, T., Adachi, Y., Kishi, H., Dang, N. H., Yamada, T., Hayakawa, Y., Morimoto, C., & Sato, T. (2023). Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies. Cells, 12(16), 2059. https://doi.org/10.3390/cells12162059

Vancouver

Kobayashi E, Kamihara Y, Arai M, Wada A, Kikuchi S, Hatano R, et al. Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies. Cells. 2023;12(16):2059. doi:10.3390/cells12162059

BibTeX
@article{Kobayashi2023,
  author = {Kobayashi, Eiji and Kamihara, Yusuke and Arai, Miho and Wada, Akinori and Kikuchi, Shohei and Hatano, Ryo and Iwao, Noriaki and Susukida, Takeshi and Ozawa, Tatsuhiko and Adachi, Yuichi and Kishi, Hiroyuki and Dang, Nam H and Yamada, Taketo and Hayakawa, Yoshihiro and Morimoto, Chikao and Sato, Tsutomu},
  title = {Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {16},
  pages = {2059},
  doi = {10.3390/cells12162059}
}
Kostenlos starten →